Breaking Canadian GLP-1 news
GLP-1 News — Page 5
Drug approvals, price changes, generic timelines, and clinical trial results affecting GLP-1 medication costs in Canada.
Where are you in your GLP-1 journey?
Answer a few quick questions — get your cheapest path to a GLP-1 prescription, free.
Tirzepatide Pricing Path: Lilly's December Cut Meets CDA Review
Eli Lilly's December 2025 Canadian price cut on Mounjaro and Zepbound dropped 2.5 mg and 5 mg doses to a $300 list, ahead of CDA's coverage review.
Apotex Pegs Generic Semaglutide at One-Third of Brand Price
Apotex says its generic semaglutide will land at roughly one-third the price of brand Ozempic as Shoppers Drug Mart and Rexall report inbound shipments.
Vital: Generic Semaglutide Reaching Canada's 10,000+ Pharmacies
Apotex began shipping generic semaglutide Tuesday while Dr. Reddy's reached select Canadian pharmacies; Rexall and Shoppers Drug Mart confirm incoming inventory.
Sandoz's Robidoux: Generic Semaglutide Road 'Longer Than Expected'
Sandoz Canada GM Michel Robidoux says generic semaglutide approval taking longer than expected as Health Canada backlog hits 100+ submissions and 84% target rate.
Generic Semaglutide Enters pCPA Tier at 85% of Brand Reference
Endor Health details how generic semaglutide enters Canada's pCPA framework at 85% of brand reference price, dropping to 55% after three months of public funding.
Felix Health begins offering generic semaglutide at $149 per pen — what we learned from their Chief Pharmacy Officer
Felix Health prices generic semaglutide at $149 per pen. Exclusive interview with their Chief Pharmacy Officer on the waitlist, supplier, and what's next.
Selectpath Warns Generics May Not Cut Canadian GLP-1 Plan Spend
Benefits advisor Selectpath warns Canadian plan sponsors that generic semaglutide may not lower total drug spend as volume rises with broader eligibility.
BMJ: $250 Unpaid Fee Opened Door to Canada's Generic Semaglutide
BMJ reports Canada is the second country to approve generic semaglutide after Novo Nordisk did not pay a C$250 annual fee, with two generics now shipping.
Generic Semaglutide Queue: Health Canada vs CMA Application Counts
Health Canada lists eight pending generic semaglutide submissions after the Dr. Reddy's approval, while CMA cited nine active applications as of late December 2025.
CPHA: Canada Now Second-Largest GLP-1 User Market Globally
Canadian Public Health Association article cites 3 million Canadian adults using GLP-1 receptor agonists in early 2026, ranking Canada second globally.
Health Canada's Johnson: Generic Semaglutide Review More Complex
Health Canada spokesperson Mark Johnson explains why generic semaglutide submissions face a more involved review than typical generics, citing synthetic peptide complexity.
Felix Tells Existing Patients: Auto-Switch to Lower Generic Price
Felix says existing semaglutide patients need take no action — their next fill will be charged at the new lower price as generic competition arrives in Canada.
Obesity Canada's Patton, McGill's Dasgupta Weigh Generic Approvals
Obesity Canada advocacy director Ian Patton calls generic semaglutide approval exciting, while McGill's Dr. Kaberi Dasgupta urges caution on over-reliance.
Canada Generics Mark Start of Semaglutide International Revenue Decline: BMO
BMO Capital Markets says Canada's two approved generic semaglutides likely mark the start of a decline in Novo Nordisk's international semaglutide revenue.
Wegovy Titration Costs $2,160-$2,280 Before Maintenance Dose in Canada
Wegovy's 16-week titration to the 2.4 mg maintenance dose costs Canadian patients $2,160-$2,280 before they reach full-dose therapy, with no provincial coverage.
Health Canada 2026-27 Plan Ties Generic Approvals to Reimbursement
Health Canada's 2026-27 Departmental Plan names pharmaceutical affordability a key priority, aligning regulatory approval with reimbursement recommendations.
CBC Correction: Novo's Semaglutide Regulatory Exclusivity Ended January
CBC corrected its generic Ozempic report to clarify Novo Nordisk's regulatory exclusivity ended in January 2026, not the patent, which expired earlier.
Novo EVP Larsen Calls Savings Card 'Leading Tactic' in Canada
Novo Nordisk EVP Emil Kongshoj Larsen told investors the company's savings card is its 'leading tactic' against Canadian generic semaglutide competitors.
Pharmacy Cash Price Gaps: Costco Undercuts Rexall by Up to $90
A 2026 price guide shows Canadian pharmacies vary by $50–$100 monthly on semaglutide cash prices, with Costco lowest and Rexall highest among major chains.
CMA: Ontario Lists Ozempic as Limited Use; Alberta Requires Step Therapy
CMA explainer details how Ontario lists Ozempic as Limited Use and Alberta treats it as step therapy, while generic semaglutide substitution rules take shape.
Looking for current pharmacy prices?
Compare GLP-1 prices across Canada